Blocking cholesterol storage to treat Alzheimer’s disease

Ta Yuan Chang*, Catherine C. Y. Chang*, Taylor C. Harned, Adrianna L. De La Torre, Junghoon Lee, Thao N. Huynh, James G. Gow
Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA

Abstract

Cholesterol serves as an essential lipid molecule in various membrane organelles of mammalian cells. The metabolites of cholesterol also play important functions. Acyl-coenzyme A: cholesterol acyltransferase 1 (ACAT1), also named as sterol O-acyltransferase 1, is a membrane-bound enzyme residing at the endoplasmic reticulum (ER). It converts cholesterol to cholesteryl esters (CEs) for storage, and is expressed in all cells. CEs cannot partition in membranes; they can only coalesce as cytosolic lipid droplets. Excess CEs are found in the vulnerable region of the brains of patients with late-onset Alzheimer’s disease (AD), and in cell and mouse models for AD. Reducing CE contents by genetic inactivation of ACAT1, or by pharmacological inhibition of ACAT is shown to reduce amyloidopathy and other hallmarks for AD. To account for the various beneficial actions of the ACAT1 blockade (A1B), a working hypothesis is proposed here: the increase in CE contents observed in the AD brain is caused by damages of cholesterol-rich lipid rafts that are known to occur in neurons affected by AD. These damages cause cholesterol to release from lipid rafts and move to the ER where it will be converted to CEs by ACAT1. In addition, the increase in CE contents may also be caused by overloading with cholesterol-rich substances, or through activation of ACAT1 gene expression by various proinflammatory agents. Both scenarios may occur in microglia of the chronically inflamed brain. A1B ameliorates AD by diverting the cholesterol pool destined for CE biosynthesis such that it can be utilized more efficiently to repair membrane damage in various organelles, and to exert regulatory actions more effectively to defend against AD. To test the validity of the A1B hypothesis in cell culture and in vivo, the current status of various anti-ACAT1 agents that could be further developed is briefly discussed.
Keywords
Alzheimer’s disease; cholesterol acyltransferase; cholesterol

Introduction
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease. Currently, it has no cure. Accumulations of extracellular amyloid plaques (known as amyloidopathy) and intracellular neurofibrillary tangles (known as tauopathy) are hallmarks of AD. In addition, an increase in cholesteryl ester (CE) contents occurs in the vulnerable region of the late-onset AD (LOAD) brain. Cholesterol plays a vital role in the brain, with cholesteryl ester being storage form of cholesterol. CE cannot substitute the function of cholesterol. Biosynthesis of CEs is carried out by the enzymes acyl-coenzyme A: cholesterol acyltransferase 1 (ACAT1) and ACAT2 [named as sterol O-acyltransferase 1 (SOAT1) and SOAT2 in GenBank]. In most cells of the human body, including the cells of central nervous system (CNS), ACAT1 is the major isoenzyme. Preclinical evidence from several laboratories implicates ACAT1 as a molecular target for the treatment of AD. Here is a brief review of the current status of the ACAT1/AD research field and the small molecule ACAT inhibitors.

Cellular cholesterol trafficking pathway in a single mammalian cell

Cholesterol is a crucial lipid molecule that plays important roles in various membrane organelles, including the plasma membrane (PM), Golgi, endosomes, peroxisomes, mitochondria, and endoplasmic reticulum (ER). Cholesterol moves in and out of these membrane organelles dynamically. The transport and movement of cholesterol occur by at least three distinct trafficking pathways (Figure 1) [1].

The first pathway involves the endocytosis/phagocytosis of extracellular materials rich in cholesterol. These materials include cholesterol-rich lipoproteins such as low-density lipoproteins (LDL), lipidated ApoE, apoptotic cell debris, and damaged cell membranes. Upon binding to various cell surface receptors, these cholesterol-rich materials are internalized and enter the early endosome. CEs contained in materials, such as LDL, are cleaved in the early endosome by acid lipase, producing free cholesterol and fatty acids [2]. Next, cholesterol moves from the early endosome to the late endosome/lysosome. There, cholesterol interacts with NPC1 and NPC2; together, they work in concert to transport cholesterol out of the late endosomes/lysosomes [2, 3]. Organelles that receive cholesterol from NPC1/NPC2 may include PM, ER, as well as trans-Golgi network [4, 5].

The second pathway involves the transport of newly synthesized sterols from the site of sterol biosynthesis (ER) to the PM; this pathway is independent of NPC1 [1, 6]. At the PM, the microdomain enriched in the lipid efflux protein ABCA1 is a favorable recipient for these newly synthesized sterols, especially lanosterol [7]. Cholesterol from exogenous uptake and cholesterol produced from endogenous biosynthesis traverse through various membrane organelles, with these two pools merging at the PM.
The third pathway is comprised of the retrograde movement of the recycling cholesterol from the PM to the ER. This pathway is independent of NPC [8, 9]. At the PM, at least three different cholesterol pools are present [10]. Several proteins including the steroidalogenic acute regulatory protein D4 [11, 12] and aster proteins/GRAM domain-containing proteins 1 [13, 14] are involved in the retrograde transport of cholesterol from PM to ER by non-vesicular lipid trafficking mechanism, perhaps through various PM/ER membrane contact site(s). In addition, ABCA1 is also involved in retrograde cholesterol transport, perhaps through a clathrin-independent endocytosis pathway [9]. These results together suggest that the movements of different cholesterol pools at the PM and the ER may be governed by different mechanisms.

AD as a special lipid disease

AD is the most prevalent neurodegenerative disease. It is classified into either early-onset AD or LOAD, with 99% of the cases being LOAD. AD pathological hallmarks consist of extracellular amyloid plaques composed of amyloid beta peptides (Aβ) especially Aβ1–42, neurofibrillary tangles composed of misfolded and hyperphosphorylated tau, and chronic neuroinflammation [15]. In addition to amyloidopathy and tauopathy, a significant amount of lipid granules, perhaps as neutral lipids (i.e., triacylglycerols and CEs), also accumulate within the glia of the AD patient brain [16]. LOAD involves numerous environmental and genetic risk factors, with aging being the strongest-known risk factor. The major genetic risk factor for LOAD is the ε4 allele of ApoE [17]. ApoE is the major lipid transport lipoprotein in the CNS. In addition to APOE ε4, about a dozen other genetic risk factors have been identified, including clustrin, ATP-binding cassette transporter A7, triggering receptor expressed on myeloid cells 2 (TREM-2), and ABCA1, all of which are involved in lipid metabolism [17–19]. Given the strong genetic association between LOAD and lipid metabolism, LOAD can be considered a unique lipid disease. Recent evidence from several laboratories supports this concept [20–22].

CE and ACAT/SOAT

CE is the storage form of cholesterol. Normally, brain CE levels are less than 1% of total cholesterol content. However, in brain samples from LOAD patients, CE levels are increased by 1.8-fold in the vulnerable regions [23]. Similarly, in the vulnerable brain regions including entorhinal cortex of three different AD mouse models, the CE levels were 3- to 11-fold higher than those in control mice [23, 24]. At the cellular level, as shown in AD patient-derived neurons, increased CE contents are linked with tau pathology [25]. These findings indicate that CE content positively correlates with AD development. What causes CEs to be elevated in AD brains is still an active area of research.

CEs stored as cytoplasmic lipid droplets exist in a dynamic state. Cholesterol esterification by the ACAT1/SOAT1 and subsequent hydrolysis by neutral CE hydrolases constitute the cholesterol/CE cycle, thus allowing CEs to undergo continuous turnover [26]. There are two ACAT genes, SOAT1 and SOAT2, encoding two homologous but distinct enzymes, ACAT1 [27] and ACAT2 [28–30], respectively. Both enzymes use long-chain fatty acyl-coenzyme A and sterols with 3-beta-OH at the steroid ring A position as substrates, this includes
cholesterol and various oxysterols (Figure 2) [31]. ACAT1 is ubiquitously expressed in essentially all cell types, including in the brain. ACAT2 is mostly expressed in intestinal enterocytes and in hepatocytes, but it is also detectable in various peripheral tissues. ACAT1 and ACAT2 are integral membrane proteins located at the ER. Unlike many enzymes in the cholesterol biosynthesis pathway (such as 3-hydroxy-3-methylglutaryl-CoA reductase), neither ACAT1 nor ACAT2 is regulated by the transcription factor sterol response element binding protein 2 [32, 33]. Instead, both ACATs are allosterically activated by its substrate cholesterol or oxysterols [34–36].

**ACAT1 blockade and AD**

Evidence from several laboratories at the preclinical level implicates ACAT1 as an important molecular target for the treatment of AD [37–43]. Mechanistically, ACAT1 blockade (A1B) offers multiple benefits to AD including the following: (1) ACAT1 gene ablation increases the content of the neuroprotective oxysterol 24(S)-hydroxycholesterol in the AD mouse brain [39] and in the AD patient induced pluripotent stem cell derived human neuronal cells [25]. (2) In mouse and cell models for amyloidopathy and tauopathy, A1B increases autophagy and lysosomal biogenesis, which leads to the clearance of Aβ oligomers in microglia [41]; A1B also increases the clearance of misfolded tau in neurons [43, 44]. (3) In AD patient-derived neurons, CEs inhibits tau proteostasis through an unknown mechanism but is independent of amyloid precursor protein and Aβ. A1B is shown to reduce CE content which prevents the inhibitory effect of CEs on tau proteostasis through an unknown mechanism. (4) A1B decreases the protein content of mutant hAPP in an AD mouse model [39], and in AD patient induced pluripotent stem cell derived human neuronal cells [25]. (5) TREM-2 deficiency has been identified as a risk factor for LOAD. TREM-2 is a membrane receptor expressed in microglia, that mediates phagocytosis of cholesterol-rich myelin debris, as well as the subsequent clearance of building CEs from the cytosol. When microglia are exposed to myelin debris, the lack of TREM-2 causes these cells to accumulate large amounts of CEs; A1B has been shown to clear the CE buildup rapidly [43].

**Cholesterol loading, CE content, and the A1B hypothesis**

Cholesterol, phosphatidylycholine, and sphingolipids can come together to form lipid raft domains/lipid clusters within cellular membranes. These lipid-rich rafts and raft-like domains are present in PM, Golgi, endosomes, and mitochondrial-associated membranes of the ER. In amyloidopathy, oligomeric Aβ interacts with cholesterol-rich lipid rafts; it is known that these interactions cause damage to the lipid rafts [1]. Here we posit that the membrane damages generated by oligomeric Aβ cause a portion of cholesterols to dissociate from the lipid rafts and move to the ER by default, followed by esterification by ACAT1. This hypothesis may explain why amyloidopathy leads to CE content to increase in various AD systems. In AD, the other major toxin is the misfolded tau. We speculate that misfolded tau may act in a similar manner as oligomeric Aβ, i.e., by damaging the lipid rafts thereby increasing the ER cholesterol content available to ACAT as substrate by default. This scenario may apply mainly to neurons that are affected by AD. A different scenario may account for the increases in CEs in microglia. Microglia are phagocytes and they actively phagocytose various substances rich in cholesterol. For examples, under
normal conditions, microglia engulf axons and synapses to eliminate immature or less active inputs. In aging and/or in various disease conditions, myelin debris and other cholesterol-rich substances, such as cell debris, apoptotic neurons, as well as damaged membrane organelles, may accumulate in the brain [45]. A special population of microglia designated as TREM-2 positive microglia actively phagocytose these materials [46]. These cholesterol-rich substances may also provide a rich source of cholesterol as substrate for ACAT1. In the mouse cortex, the ACAT1 transcript in microglia is significantly higher than those in other cell types in the CNS [47]. Based on these analyses, we predict that the CE content in microglia may be higher than those in other cell types, perhaps in brain region specific manner. The scenario discussed above focuses on increasing the cholesterol supply to ACAT as a substrate as the cause for the increases in CEs. In addition to an increase in substrate supply, cell culture study in macrophages showed that ACAT1 gene and ACAT1 protein content are up-regulated by the proinflammatory cytokine tumor necrosis factor-alpha [48]. Since AD involves chronic inflammation, it is possible that brain inflammation in AD leads to the accumulation of several proinflammatory cytokines which then cause the increase in ACAT1 gene expression and in ACAT1 protein content. The increased ACAT1 protein content will lead to increased CE production.

To provide a rationale for the A1B effects in a single cell, we posit that A1B causes the cholesterol pool at the vicinity of ACAT1 to build up. Cholesterol in excess of binding to PC/sphingolipid becomes “mobile cholesterol”, which tends to move away from the ER to other membrane organelles, including the Golgi, endosome, PM, etc., thus increasing their respective free cholesterol contents [49]. In AD, the mobile cholesterol produced by A1B helps to repair the functional deficiency of lipid rafts in the membranes damaged by oligomeric Aβ and/or by tau. A1B also increases regulatory responses located at the ER which facilitate cellular cholesterol homeostasis [1]. Targeting microglia has been considered as an effective approach to treat AD and other neurodegenerative diseases. It will be interesting to test whether the effects of A1B are more robust in microglia, especially when they are cholesterol-loaded.

The pros and cons of the A1B approach to treat LOAD

The validity of the A1B hypothesis needs to be further tested in various cell culture systems and in vivo. Aging and ApoE4 are two major risk factors for LOAD. Therefore, the effects of A1B need to be examined in animal models for aging, preferably in ApoE isoform-specific manner. The excess build-up of free cholesterol in cells can cause toxicity. To prevent this toxicity, the major lipid efflux protein ABCA1 plays a key role in assisting the disposal of cholesterol at the PM [50]. Fortunately, in various cell types examined, A1B increased the protein content of ABCA1, as well as the capacity of ABCA1 to efflux cellular cholesterol [51]. Therefore, in normal situation, A1B is not expected to cause free cholesterol to build up intracellularly. Still, it is important to test the effects of A1B in cells without significant deficiency in ABCA1 and/or in other related proteins involved in the reverse cholesterol pathway. It is also important to know that in mouse models, genetic inactivation of ACAT1 caused dry eye syndrome, hair loss, and increased leukocyte production. In our opinion, the adverse effects can be used to predict drug overdose of A1B in vivo.
Possible link between the \(ACAT1/\text{SOAT1}\) single-nucleotide polymorphism with AD risk

A recent study reported that among one of the four common \(ACAT1/\text{SOAT1}\) polymorphisms investigated, one protective haplotype and one risk haplotype for the development of dementia have been found [52]. The first single-nucleotide polymorphism (SNP) is located in exon 14 [53], but the change in nucleotide does not cause change in amino acid (i.e., a synonymous mutation). The second SNP is located at the 3’ UTR region of the \(ACAT1/\text{SOAT1}\) mRNA [27], whose link with AD risk has been previously reported [54]. The functional significance of these two SNPs is unknown at present and awaits further investigation.

Small molecule ACAT inhibitors to treat atherosclerosis or AD

ACAT has been a drug target to treat atherosclerosis and many ACAT inhibitors have already been produced. The characteristics of several ACAT inhibitors and their status as anti-atherosclerosis drugs are listed (Table 1).

CI1011 is an isoform non-specific ACAT inhibitor; it inhibits both ACAT1 and ACAT2 with modest inhibition constant (Ki). CI1011 successfully completed clinical testing, however, it was abandoned because it lacked efficacy as a supplement to the statin drugs (the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors), to further reduce serum cholesterol levels in patients with hypercholesterolemia [55]. The lack of efficacy of CI1011 was in part due to its drug-drug interaction with statins [56].

Pactimibe is a second-generation derivative of CI1011; it also failed to supplement the actions of statins in patients [57].

CP113818 is a high-affinity, isoform-non-specific ACAT inhibitor (Ki = 0.02 \(\mu\text{mol/L}\)). Animal studies showed that CP113818 accumulated in adrenal cell membranes and caused toxicity (unpublished observations made by scientists at Pfizer). CP113818 possesses an asymmetric carbon (Figure 3). This asymmetry is needed in order for CP113818 to act as a potent ACAT inhibitor. The enantiomeric isomers of CP113818 (and its close analogs) are inactive as ACAT inhibitors, however, they also cause severe adrenal toxicities [58]. Thus, the toxicity of CP113818 (and their close analogs) might be caused by their properties as membrane-active compounds, which enabled them to be highly enriched in adrenal cell membranes, instead of its ability to inhibit ACAT [59]. Supporting this interpretation is the genetic evidence that the adrenal functions of mice globally devoid of \(ACAT1\) is normal [60].

To improve the pharmacological properties of CP113818, scientists at Pierre Fabre in France produced F12511 as a second-generation derivative of CP113818. F12511 also contains an asymmetric center (Figure 3) and is a high-affinity ACAT1 inhibitor (Ki = 0.039 \(\mu\text{mol/L}\)) that also inhibits ACAT2 with Ki = 0.11 \(\mu\text{mol/L}\). Unlike 113818, F12511 did not cause adrenal toxicity in animals, and passed the clinical safety test in humans as an
anti-atherosclerosis drug candidate but F12511 was abandoned for undisclosed reason(s) [61, 62].

K604 is a second-generation derivative of pactimibe (described earlier) and is a high-affinity ACAT1-specific inhibitor with Ki = 0.45 μmol/L [63]. It also passed the clinical safety test but was abandoned for undisclosed reason(s).

The analysis described in Figure 2 shows that the toxicity of the ACAT inhibitors can be avoided or minimized by careful chemical modification of the lead compound(s). In a mouse model for AD, Kovacs and colleagues showed that, when delivered by implanting CP113818 as a slow releasing pellet underneath the mouse skin, CP113818 was effective in suppressing amyloidopathy [38]. This was the first animal study suggesting that certain ACAT inhibitors originally designed for treating atherosclerosis can be repurposed to treat AD. Whether F12511 or K604 is effective in mouse models for AD has not been reported in the literature.

**Adeno-associated viral expression of small interfering RNA against Acat1/Soat1 to treat AD**

Adeno-associated viruses (AAVs) are considered as major gene therapy vectors because they produce long-term (at least one year), stable, episomal expression of the viral transgene, provoke only a minimal inflammatory response, have minimal oncogenic potential, and can infect and transduce various postmitotic cells including neurons and astrocytes. Many laboratories have used this strategy as potential gene therapy to treat animal models for neurodegenerative diseases [64]. In a mouse disease model for early-onset AD, delivering a specific AAV-siRNA against Acat1 by direct injection into mouse hippocampus significantly reduced ACAT1 enzyme activity in the brain and reduced amyloidopathy [40]. This work suggests that AAV-siRNA against Acat1 can be considered as a potential therapy to treat AD and other related neurodegenerative diseases.

**Conclusion and perspectives**

AD is a neurodegenerative disease that currently has no cure. LOAD involves numerous environmental and genetic risk factors, and leads to cholesterol dyshomeostasis in the CNS. In various experimental AD systems, A1B has been reported to provide multiple benefits. Here we propose a simple working hypothesis to account for the beneficial actions of A1B within a single cell:

A. In neurons, Aβ and misfolded tau dissociate cholesterol from the lipid clusters in various membrane organelles, causing more cholesterol to move to the ER by default and to serve as ACAT1 substrate.

B. In microglia, aging and other AD risk factors ultimately increase cholesterol supply to ACAT1.

C. In various cell types of the brain affected by AD, TNF-alpha and other proinflammatory factors increase ACAT1 gene expression and ACAT1 protein content.
D. In various cell types, blocking ACAT1 causes the cholesterol substrate pool to move away from the ACAT1 domain at the ER, and into various other membrane organelles, including the Golgi, endosome, PM, etc., where it will be utilized more efficiently.

The validity of this hypothesis needs rigorous testing in animal studies and in human systems. The current status of various small molecule ACAT inhibitors to treat atherosclerosis and AD, and the use of AAV-siRNA against Acat1 to treat mouse model of AD is reviewed here. Hopefully, these agents will be used to test this hypothesis, and to be further developed to help ameliorate LOAD. Other neurodegenerative diseases, including Niemann-pick type C disease [65, 66], amyotrophic lateral sclerosis [67], Huntington disease [68, 69], and adult glioma [70, 71], also involve cholesterol dysshomeostasis in the brain. Diverting cholesterol from conversion to CEs by inhibiting the cholesterol storage enzyme ACAT1 to increase cholesterol utilization may also benefit these diseases.

**Funding**

This work is supported financially by NIH grant AG AG037609 to TYC and CCYC. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| Aβ           | amyloid beta peptides |
| A1B          | acyl-coenzyme A: cholesterol acyltransferase 1 blockade |
| AAVs         | adeno-associated viruses |
| ABCA1        | ATP-binding cassette transporter A1 |
| ACAT1        | acyl-coenzyme A: cholesterol acyltransferase 1 |
| AD           | Alzheimer’s disease |
| ApoE         | apolipoprotein E |
| CEs          | cholesteryl esters |
| CNS          | central nervous system |
| ER           | endoplasmic reticulum |
| Ki           | inhibition constant |
| LOAD         | late-onset of Alzheimer’s disease |
| NPC          | Niemann-pick type C proteins |
| PM           | plasma membrane |
| SNP          | single-nucleotide polymorphism |
| SOAT1        | sterol O-acyltransferase 1 |
TREM-2 triggering receptor expressed on myeloid cells 2

References

1. Chang TY, Yamauchi Y, Hasan MT, Chang C. Cellular cholesterol homeostasis and Alzheimer’s disease. J Lipid Res. 2017;58:2239–54. [PubMed: 28298292]
2. Storch J, Xu Z. Niemann-pick C2 (NPC2) and intracellular cholesterol trafficking. Biochim Biophys Acta. 2009;1791:671–8. [PubMed: 19232397]
3. Pfeffer SR. NPC intracellular cholesterol transporter 1 (NPC1)-mediated cholesterol export from lysosomes. J Biol Chem. 2019;294:1706–9. [PubMed: 30710017]
4. Urano Y, Watanabe H, Murphy SR, Shibuya Y, Geng Y, Peden AA, et al. Transport of LDL-derived cholesterol from the NPC1 compartment to the ER involves the trans-Golgi network and the SNARE protein complex. Proc Natl Acad Sci U S A. 2008;105:16513–8. [PubMed: 18946045]
5. Reverter M, Rentero C, de Muga SV, Alvarez-Guaita A, Mulay V, Cairns R, et al. Cholesterol transport from late endosomes to the Golgi regulates t-SNARE trafficking, assembly, and function. Mol Biol Cell. 2011;22:4108–23. [PubMed: 22039070]
6. Liscum L, Dahl NK. Intracellular cholesterol transport. J Lipid Res. 1992;33:1239–54. [PubMed: 1402394]
7. Yamauchi Y, Yokoyama S, Chang TY. ABCA1-dependent sterol release: sterol molecule specificity and potential membrane domain for HDL biogenesis. J Lipid Res. 2016;57:77–88. [PubMed: 26497474]
8. Ali-Mosleh L, Infante RE, Radhakrishnan A, Goldstein JL, Brown MS. Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-pick type C cells. Proc Natl Acad Sci U S A. 2009;106:19316–21. [PubMed: 19884502]
9. Yamauchi Y, Iwamoto N, Rogers MA, Abe-Dohmae S, Fujimoto T, Chang CCY, et al. Deficiency in the lipid exporter ABCA1 impedes retrograde sterol movement and disrupts sterol sensing at the endoplasmic reticulum. J Biol Chem. 2015;290:23464–77. [PubMed: 26198636]
10. Das A, Brown MS, Anderson DD, Goldstein JL, Radhakrishnan A. Three pools of plasma membrane cholesterol and their relation to cholesterol homeostasis. Elife. 2014;3:e02882.
11. Mesmin B, Pipalia NH, Lund FW, Ramllat TF, Sokolov A, Eliezer D, et al. STARD4 abundance regulates sterol transport and sensing. Mol Biol Cell. 2011;22:4004–15. [PubMed: 21900492]
12. Garbarino J, Pan M, Chin HF, Lund FW, Maxfield FR, Breslow JL. STARD4 knockdown in HepG2 cells disrupts cholesterol trafficking associated with the plasma membrane, ER, and ERC. J Lipid Res. 2012;53:2716–25. [PubMed: 23033213]
13. Sandhu J, Li S, Fairall L, Pfisterer SG, Gurnett JE, Xiao X, et al. Aster proteins facilitate nonvesicular plasma membrane to ER cholesterol transport in mammalian cells. Cell. 2018;175:514–29.e20. [PubMed: 30220461]
14. Naito T, Ercan B, Krshnan L, Triebl A, Koh DHZ, Wei FY, et al. Movement of accessible plasma membrane cholesterol by the GRAMD1 lipid transfer protein complex. Elife. 2019;8:e51401. [PubMed: 31724953]
15. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405. [PubMed: 25792098]
16. Foley P. Lipids in Alzheimer’s disease: a century-old story. Biochim Biophys Acta. 2010;1801:750–3. [PubMed: 20471492]
17. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68:270–81. [PubMed: 2095934]
18. Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ, et al. Genome-wide association meta-analysis of neuropathologic features of Alzheimer’s disease and related dementias. PLoS Genet. 2014;10:e1004606. [PubMed: 25188341]
19. Nordestgaard LT, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Loss-of-function mutation in ABCA1 and risk of Alzheimer’s disease and cerebrovascular disease. Alzheimers Dement. 2015;11:1430–8. [PubMed: 26079414]

Explor Neuroprotective Ther. Author manuscript; available in PMC 2022 February 22.
20. Sienski G, Narayan P, Bonner JM, Kory N, Boland S, Arczewska AA, et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. Sci Transl Med. 2021;13:eaz4564. [PubMed: 33658354]

21. Guttenplan KA, Weigel MK, Prakash P, Wijewardhane PR, Hasel P, Rufen-Blanchette U, et al. Neurotoxic reactive astrocytes induce cell death via saturated lipids. Nature. 2021;599:102–7. [PubMed: 34616039]

22. Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proc Natl Acad Sci U S A. 2021;118:e2102191118. [PubMed: 34385305]

23. Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem. 2012;287:2678–88. [PubMed: 22134919]

24. Tajima Y, Ishikawa M, Maekawa K, Murayama M, Senoo Y, Nishimaki-Mogami T, et al. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer’s disease. Lipids Health Dis. 2013;12:68. [PubMed: 23659495]

25. van der Kant R, Langness VF, Herrera CM, Williams DA, Fong LK, Leestemaker Y, et al. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-beta in iPSC-derived Alzheimer’s disease neurons. Cell stem cell. 2019;24:363–75.e9. [PubMed: 30686764]

26. Brown MS, Ho YK, Goldstein JL. The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem. 1980;255:9344–52. [PubMed: 7410428]

27. Chang CC, Huh HY, Cadigan KM, Chang TY. Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells. J Biol Chem. 1993;268:20747–55. [PubMed: 8407899]

28. Anderson RA, Joyce C, Davis M, Reagan JW, Clark M, Shelness GS, et al. Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J Biol Chem. 1998;273:26747–54. [PubMed: 9756918]

29. Cases S, Novak S, Zheng YW, Myers HM, Lear SR, Sande E, et al. ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. Its cloning, expression, and characterization. J Biol Chem. 1998;273:26755–64. [PubMed: 9756919]

30. Oelkers P, Behari A, Cromley D, Billheimer JT, Sturley SL. Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes. J Biol Chem. 1998;273:26755–71. [PubMed: 9756920]

31. Liu J, Chang CCY, Westover EJ, Covey DF, Chang TY. Investigating the allosterism of acyl CoA:cholesterol acyltransferase (ACAT) by using various sterols: in vitro and intact cell studies. Biochem J. 2005;391:389–97. [PubMed: 15992359]

32. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124:35–46. [PubMed: 16143480]

33. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161:161–72. [PubMed: 25815993]

34. Chang CC, Chen J, Thomas MA, Cheng D, Del Priore VA, Newton RS, et al. Regulation and immunolocalization of acyl-coenzyme A: cholesterol acyltransferase in mammalian cells as studied with specific antibodies. J Biol Chem. 1995;270:29532–40. [PubMed: 7493995]

35. Cheng D, Chang CC, Qu X, Chang TY. Activation of acyl-coenzyme A:cholesterol acyltransferase by cholesterol or by oxysterol in a cell-free system. J Biol Chem. 1995;270:685–95. [PubMed: 7822296]

36. Chang TY, Li BL, Chang CCY, Urano Y. Acyl-coenzyme A:cholesterol acyltransferases. Am J Physiol Endocrinol Metab. 2009;297:E1–9. [PubMed: 19141679]

37. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol. 2001;3:905–12. [PubMed: 11584272]
38. Hutter-Paier B, Huttenen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron. 2004;44:227–38. [PubMed: 15473963]

39. Bryleva EY, Rogers MA, Chang CCY, Buen F, Harris BT, Rousselet E, et al. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A. 2010;107:3081–6. [PubMed: 20133765]

40. Murphy SR, Chang CC, Dogbevia G, Bryleva EY, Bowen Z, Hasan MT, et al. ACAT1 knockdown gene therapy decreases amyloid-beta in a mouse model of Alzheimer’s disease. Mol Ther. 2013;21:1497–506. [PubMed: 23774792]

41. Shibuya Y, Chang CCY, Huang LH, Bryleva EY, Chang TY. Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Aβ1–42 clearance. J Neurosci. 2014;34:14484–501. [PubMed: 25339759]

42. Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS, et al. TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron. 2020;105:837–54.e9. [PubMed: 31902528]

43. Shibuya Y, Niu Z, Bryleva EY, Harris BT, Murphy SR, Kheirollah A, et al. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer’s disease mouse and reduces human P301L-tau content at the presymptomatic stage. Neurobiol Aging. 2015;36:2248–59. [PubMed: 25930235]

44. Shibuya Y, Chang CC, Chang TY. ACAT1/SOAT1 as a therapeutic target for Alzheimer’s disease. Future Med Chem. 2015;7:2451–67. [PubMed: 26669800]

45. Hong S, Dissing-Olesen L, Stevens B. New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol. 2016;36:128–34. [PubMed: 26745839]

46. Loving BA, Bruce KD. Lipid and lipoprotein metabolism in microglia. Front Physiol. 2020;11:393. [PubMed: 32411016]

47. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929–47. [PubMed: 25186741]

48. Lei L, Xiong Y, Chen J, Yang JB, Wang Y, Yang XY, et al. TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation. J Lipid Res. 2009;50:1057–67. [PubMed: 19189937]

49. Lange Y, Steck TL. Active membrane cholesterol as a physiological effector. Chem Phys Lipids. 2016;199:74–93. [PubMed: 26874289]

50. Oram JF, Heinecke JW. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev. 2005;85:1343–72. [PubMed: 16183915]

51. Yamauchi Y, Chang CCY, Hayashi M, Abe-Dohmae S, Reid PC, Chang TY, et al. Intracellular cholesterol mobilization involved in the ABCA1/apolipoprotein-mediated assembly of high density lipoprotein in fibroblasts. J Lipid Res. 2004;45:1943–51. [PubMed: 15292375]

52. Alavez-Rubio JS, Martinez-Rodriguez N, Escobedo-de-la-Pena J, Garrido-Acosta O, Juarez-Cedillo T. Relationship between genetic variants of ACAT1 and APOE with the susceptibility to dementia (SADEM Study). Mol Neurobiol. 2021;58:905–12. [PubMed: 33057949]

53. Li BL, Li XL, Duan ZJ, Lee O, Lin S, Ma ZM, et al. Human acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) gene organization and evidence that the 4.3-kilobase ACAT-1 mRNA is produced from two different chromosomes. J Biol Chem. 1999;274:11060–71. [PubMed: 10196189]

54. Wollmer MA, Streffer JR, Tsolaki M, Grimaldi LME, Lutjohann D, Thal D, et al. Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer’s disease. Mol Psychiatry. 2003;8:635–8. [PubMed: 12851640]

55. Tardif JC, Greigore J, L’Allier PL, Anderson TJ, Bertrand O, Reeves F, et al. Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation. 2004;110:3372–7. [PubMed: 15533865]
56. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006;354:1253–63. [PubMed: 16554527]

57. Sahi J, Milad MA, Zheng X, Rose KA, Wang H, Stilgenbauer L, et al. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J Pharmacol Exp Ther. 2003;306:1027–34. [PubMed: 12766253]

58. Riddell D, Bright CP, Burton BJ, Bush RC, Harris NV, Hele D, et al. Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol. Biochem Pharmacol. 1996;52:1177–86. [PubMed: 8937424]

59. Sliskovic DR, Picard JA, Krause BR. ACAT inhibitors: the search for a novel and effective treatment of hypercholesterolemia and atherosclerosis. Prog Med Chem. 2002;39:121–71. [PubMed: 12536672]

60. Meiner VL, Cases S, Myers HM, Sande ER, Bellosta S, Schambelan M, et al. Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: evidence suggesting multiple cholesterol esterification enzymes in mammals. Proc Natl Acad Sci U S A. 1996;93:14041–6. [PubMed: 8943057]

61. Burnett JR. Eflucimibe. Pierre Fabre/Eli Lilly. Curr Opin Investig Drugs. 2003;4:347–51.

62. Lopez-Farre AJ, Sacristan D, Zamorano-Leon JJ, San-Martin N, Macaya C. Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (eflucimibe): could it be a new antiatherosclerotic therapeutic? Cardiovasc Ther. 2008;26:65–74. [PubMed: 18466422]

63. Ikenoya M, Yoshinaka Y, Kobayashi H, Kawamine K, Shibuya K, Sato F, et al. A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007;191:290–7. [PubMed: 16820149]

64. Hudry E, Vandenberghé LH. Therapeutic AA V gene transfer to the nervous system: a clinical reality. Neuron. 2019;101:839–62. [PubMed: 30844402]

65. Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, et al. Niemann-pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science. 1997;277:228–31. [PubMed: 9211849]

66. Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, et al. Identification of HE1 as the second gene of Niemann-pick C disease. Science. 2000;290:2298–301. [PubMed: 11125141]

67. Ho WY, Chang JC, Lim K, Cazenave-Gassiot A, Nguyen AT, Foo JC, et al. TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination. J Cell Biol. 2021;220:e201910213. [PubMed: 34347016]

68. Valenza M, Carroll JB, Leoni V, Bertram LN, Bjorkhem I, Singaraja RR, et al. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum Mol Genet. 2007;16:2187–98. [PubMed: 17613541]

69. Leoni V, Caccia C. The impairment of cholesterol metabolism in Huntington disease. Biochim Biophys Acta. 2015;1851:1095–105. [PubMed: 25596342]

70. Bemlih S, Poirier MD, El Andaloussi A. Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines. Cancer Biol Ther. 2010;9:1025–32. [PubMed: 20404512]

71. Ohmoto T, Nishitsuji K, Yosihitani N, Mizuguchi M, Yanagisawa Y, Saito H, et al. K604, a specific acyl CoA:cholesterol acyltransferase 1 inhibitor, suppresses proliferation of U251 MG glioblastoma cells. Mol Med Rep. 2015;12:6037–42. [PubMed: 26252415]

*Explor Neuroprotective Ther. Author manuscript; available in PMC 2022 February 22.*
Figure 1.
The cellular cholesterol trafficking pathway in a mammalian cell. ABCA1: ATP-binding cassette transporter 1; ApoE: apolipoprotein E; AL: acid lipase; C: cholesterol; CEH: cholesterol ester hydrolase; EE: early endosomes; ERC: endocytic recycling compartment; HMGR: HMG-CoA reductase receptors; LE: late endosomes; NPC: Niemann-pick type C proteins; PL: phospholipid; SREBP: sterol-regulatory-element binding protein; SCAP: SREBP cleavage activating protein

Note. Adapted from “Cellular cholesterol homeostasis and Alzheimer’s disease,” by Chang TY, Yamauchi Y, Hasan MT, Chang C. J Lipid Res. 2017;58:2239–54 (https://doi.org/10.1194/jlr.R075630). © 2017 ASBMB. CC BY.
Figure 2.
Biochemical reaction catalyzed by the enzyme ACAT/SOAT
Figure 3.
Comparison of 2 high-affinity ACAT inhibitors CP113818 and F12511

CP113818
$K_i^{ACAT_1} = 0.020 \, \mu\text{mol/L}$
$K_i^{ACAT_2} = 0.020 \, \mu\text{mol/L}$
Failed in pre-clinical safety test for anti-atherosclerosis

F12511 (eflacimibe)
$K_i^{ACAT_1} = 0.039 \, \mu\text{mol/L}$
$K_i^{ACAT_2} = 0.110 \, \mu\text{mol/L}$
Passed clinical safety test for anti-atherosclerosis
Table 1.

ACAT inhibitors for anti-atherosclerosis purpose

| Inhibitors       | Ki (μmol/L) | Status                                      |
|------------------|-------------|---------------------------------------------|
|                  | ACAT1   | ACAT2                                       |
| CI976            | 5.9       | 2.1                                         |
|                  | Failed at pre-clinical stage (Parke-Davis) |
| ATR101 (nevanimibe) | 0.23     | Failed at pre-clinical stage (Parke-Davis)  |
| CP113818         | 0.02      | 0.02                                        |
|                  | Failed at pre-clinical stage (Pfizer)     |
| CI1011           | 19        | 19                                          |
|                  | Abandoned after phase 3 (Pfizer)          |
| CS505 (pactimibe)| 4.9       | 3                                           |
|                  | Abandoned after phase 3 (Sankyo)          |
| K604             | 0.45      | 102.9                                       |
|                  | Abandoned after phase 2 trial (Kowa)      |
| F12511           | 0.039     | 0.11                                        |
|                  | Abandoned after phase 1 trial (Lilly)     |